Report copyright - MERCK ONCOLOGY OVERVIEW ASCO 2018 · 2018. 6. 4. · 5 Melanoma KEYNOTE-054: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ASCO 2018 SPOTLIGHT
Please pass captcha verification before submit form